“Most Favored Nation” Drug Pricing Hurts Patients, Innovation, and New Jersey Jobs
- 5 days ago
- 1 min read
By: Dan Leonard, Executive Director, We Work For Health and Chrissy Buteas, President and Chief Executive Officer, HealthCare Institute of New Jersey
Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricing policy – which would tie U.S. prices to those set by foreign governments – it would come at an extraordinary cost to patients, America’s scientific leadership, and New Jersey jobs.
Importing foreign healthcare prices also means importing the trade-offs embedded in other countries’ healthcare systems – trade-offs that often result in fewer treatment options, delayed access to new medicines, and reduced investment in the next generation of cures.